drugset / Trial / NCT04905316
A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
Phase 2
Completed
41 enrolled
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether canakinumab in combination with chemoradiation and durvalumab is an effective and safe treatment for people with locally advanced non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2021-05-21
- Primary completion
- 2026-07-06
- Completion
- 2026-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 200 mg | Subcutaneous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Durvalumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Background | Etoposide | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |